Solution providers and innovators of the pharma and healthcare industry, as well as experts in clinical trials, are invited to attend the 21st Biopharma Clinical Trials Nexus at the Holiday Inn Piscataway, Somerset, in New Jersey. This is an invite-only event that will be held from October 22, 2024, to October 23, 2024.
BioPharma Nexus focuses on creating synergies between leading pharmaceutical and biotechnology entities, along with service providers. Their objective is to provide high-quality healthcare to patients all over the globe. At the BioPharma Nexus conferences, players can explore, discover, and generate…
Read More>>
To learn more, please visit https://ibn.fm/nRQpt.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
